5 Matching Annotations
  1. Mar 2021
  2. www.thelancet.com www.thelancet.com
    What does 95% COVID-19 vaccine efficacy really mean?
    1
    1. jasminehollingworth 15 Mar 2021

      Olliaro, P. (2021). What does 95% COVID-19 vaccine efficacy really mean? The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00075-X

      lang:en is:article COVID-19 vaccine vaccination efficacy effectiveness symptomatic population disease disease protection misconception reduction risk exposure transmission
    Visit annotations in context

    Tags

    Annotators

    URL

    thelancet.com/journals/laninf/article/PIIS1473-3099(21)00075-X/fulltext
  3. Dec 2020
  4. www.theguardian.com www.theguardian.com
    WHO looks at giving Covid-19 to healthy people to speed up vaccine trials
    1
    1. marta_radosevic 23 Dec 2020

      Grover, N. (2020, December 7). WHO looks at giving Covid-19 to healthy people to speed up vaccine trials. The Guardian. https://www.theguardian.com/world/2020/dec/07/who-looks-at-giving-covid-to-healthy-people-to-speed-up-vaccine-trials

      is:news lang:en COVID-19 vaccine WHO human trial healthy population risk young healthy exposure benefit research
    Visit annotations in context

    Tags

    Annotators

    URL

    theguardian.com/world/2020/dec/07/who-looks-at-giving-covid-to-healthy-people-to-speed-up-vaccine-trials
  5. Sep 2020
  6. link.springer.com link.springer.com
    Difference-in-Difference in the Time of Cholera: a Gentle Introduction for Epidemiologists
    1
    1. Gaurav_Saxena 26 Sep 2020

      Caniglia, E.C., Murray, E.J. (2020) Difference-in-Difference in the Time of Cholera: a Gentle Introduction for Epidemiologists. Current Epidemiology Reports. https://doi.org/10.1007/s40471-020-00245-2

      is:article lang:en epidemiology difference-indifference method population exposure cholera UK
    Visit annotations in context

    Tags

    Annotators

    URL

    link.springer.com/article/10.1007/s40471-020-00245-2
  7. www.medrxiv.org www.medrxiv.org
    Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany
    1
    1. ErikStuchly 02 Sep 2020

      Aziz, N. A., Corman, V. M., Echterhoff, A. K. C., Richter, A., Schmandke, A., Schmidt, M. L., Schmidt, T. H., Vries, F. M. D., Drosten, C., & Breteler, M. M. B. (2020). Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany. MedRxiv, 2020.08.24.20181206. https://doi.org/10.1101/2020.08.24.20181206

      is:preprint lang:en COVID-19 seroprevalence correlate neutralization antibody population-based Germany estimate exposure symptom
    Visit annotations in context

    Tags

    Annotators

    URL

    medrxiv.org/cgi/content/10.1101/2020.08.24.20181206
  8. May 2020
  9. dash.harvard.edu dash.harvard.edu
    Implications of test characteristics and population seroprevalence on ‘immune passport’ strategies
    1
    1. edampf 13 May 2020

      Larremore, Daniel B., Kate M. Bubar, and Yonatan H. Grad. Implications of test characteristics and population seroprevalence on ‘immune passport’ strategies (May 2020).https://dash.harvard.edu/handle/1/42664007

      is:article lang:en COVID-19 immunity passport return to work population seroprevalence testing prevention infection transmission reduction antibody exposure implication
    Visit annotations in context

    Tags

    Annotators

    URL

    dash.harvard.edu/handle/1/42664007